Abstract
The primary, enduring negative symptoms found in some patients with schizophrenia have become the focus of clinical treatment trials, but there has been no consensus on the best methods for approaching this area. In future trials, a number of issues need to be considered, including analytic strategies, the limitations in instruments used to measure negative symptoms, and study design. An appropriate design for establishing the efficacy of treatments for the deficit syndrome is proposed.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Amador XF, Kirkpatrick B, Buchanan RW, Carpenter WT, Marcinko L, Yale SA . (1999): Stability of the diagnosis of deficit syndrome in schizophrenia. Am J Psychiatry 156: 637–639
Andreasen NC . (1982): Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 39: 784–788
Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M . (1995): Symptoms of schizophrenia. Methods, meanings, and mechanisms. Arch Gen Psychiatry 52: 341–351
Andreasen NC, Olsen S . (1982): Negative v. positive schizophrenia. Definition and validation. Arch Gen Psychiatry 39: 789–794
Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F . (1995): Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166: 68–72
Breckler SJ, Steven J . (1990): Applications of covariance structure modeling in psychology: Cause for concern? Psychol Bull 107: 260–273
Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr . (1994): Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 151: 20–26
Buchanan RW, Brandes M, Breier A . (1996): Pharmacological strategies for treating negative symptoms. In Breier A (ed), The New Pharmacotherapy of Schizophrenia. Washington, DC, American Psychiatric Press, pp 179–204
Buchanan RW, Carpenter WT . (1994): Domains of psychopathology: An approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis 182: 193–204
Buchanan RW, Kirkpatrick B, Heinrichs DW, Carpenter WT Jr . (1990): Clinical correlates of the deficit syndrome of schizophrenia. Am J Psychiatry 147: 290–294
Buchanan RW, Breier A, Kirkpatrick B, Elkashef A, Munson RC, Gellad F, Carpenter WT . (1993): Structural abnormalities in deficit vs. non-deficit schizophrenia. Am J Psychiatry 150: 59–65
Buchanan RW, Strauss ME, Kirkpatrick B, Holstein C, Breier A, Carpenter WT Jr. . (1994): Neuropsychological impairments in deficit vs. nondeficit forms of schizophrenia. Arch Gen Psychiatry 51: 804–811
Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr . (1998): Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 155: 751–760
Buchanan RW, Strauss ME, Breier A, Kirkpatrick B, Carpenter WT Jr . (1997): Attentional impairments in deficit and nondeficit forms of schizophrenia. Am J Psychiatry 154: 363–370
Bustillo JR, Thaker G, Buchanan RW, Moran M, Kirkpatrick B, Carpenter WT . (1997): Visual information-processing impairments in deficit and nondeficit schizophrenia. Am J Psychiatry 154: 647–654
Carpenter WT Jr, Lahti AC, Holcomb HH, Zhao M, Buchanan RW, Tamminga CA . (1996): Frontal and parietal blood flow activation during an auditory task differentiate schizophrenic patients with and without primary negative symptoms. Abst Soc Neurosci 22: 268.4.
Carpenter WT Jr, Heinrichs DW, Alphs LD . (1985): Treatment of negative symptoms. Schizophr Bull 11: 440–452
Carpenter WT Jr, Heinrichs DW, Wagman AM . (1988): Deficit and nondeficit forms of schizophrenia: The concept. Am J Psychiatry 145: 578–583
Collaborative Working Group on Clinical Trial Evaluations. (1998): Assessing the effects of atypical antipsychotics on negative symptoms. J Clin Psychiatry 59 (Suppl 12):28–34
Crow TJ . (1985): The two-syndrome concept: origins and current status. Schizophr Bull 11: 471–486
Dollfus S, JM Ribeyre, M Petit . (1996): Family history and deficit form in schizophrenia. Eur Psychiatry 11: 260–267
Fenton WS, McGlashan TH . (1992): Testing systems for assessment of negative symptoms in schizophrenia. Arch Gen Psychiatry 49: 179–184
Fenton WS, McGlashan TH . (1994): Antecedents, symptoms progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry 151: 351–356
Flaum M, Andreasen N . (1995): The reliability of distinguishing primary versus secondary negative symptoms. Comprehen Psychiatry 36: 421–427
Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT . (1999): A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56 (1): 21–27
Goldberg SC . (1985): Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 11: 453–456
Gur RE, Mozley PD, Shtasel DL, Cannon TD, Gallacher F, Turetsky B, Grossman R, Gur RC . (1994): Clinical subtypes of schizophrenia: Differences in brain and CSF volume. Am J Psychiatry 151: 343–350
Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M . (1999): Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56: 29–36
Kirkpatrick B, Amador XF, Flaum M, Yale SA, Gorman JM, Carpenter WT Jr, Tohen M, McGlashan T . (1996a): The deficit syndrome in the DSM-IV Field Trial. I. Alcohol and other drug abuse. Depressive episodes and persecutory beliefs. Schizophr Res 20: 67–78
Kirkpatrick B, Amador XF, Yale SA, Bustillo JR, Buchanan RW, Tohen M . (1996b): The deficit syndrome in the DSM-IV Field Trial. Part II. Depressive episodes and persecutory beliefs. Schizophr Res 20: 79–90
Kirkpatrick B, Buchanan RW . (1990): Anhedonia and the deficit syndrome of schizophrenia. Psychiatry Res 31: 25–30
Kirkpatrick B, Buchanan RW, Breier A, Carpenter WT Jr . (1993): Case identification and stability of the deficit syndrome of schizophrenia. Psychiatry Res 47: 47–56
Kirkpatrick B, Buchanan RW, Breier A, Carpenter WT Jr . (1994): Depressive symptoms and the deficit syndrome of schizophrenia. J Nerv Ment Dis 182: 452–455
Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr . (1989): The Schedule for the Deficit Syndrome: An instrument for research in schizophrenia. Psychiatry Res 30: 119–124
Kirkpatrick B, Castle D, Murray RM, Carpenter WT . (1999): Risk factors for the deficit syndrome of schizophrenia. Schizophr Bull, in press.
Kirkpatrick B, Ram R, Amador XF, Buchanan RW, McGlashan T, Tohen M, Bromet E . (1998): Summer birth and the deficit syndrome of schizophrenia. Am J Psychiatry 155: 1221–1226
Kirkpatrick B, Ram R, Bromet E . (1996c): The deficit syndrome in the Suffolk County Mental Health Project. Schizophr Res 22: 119–126
Kopelowicz A, Liberman RP, Mintz J, Zarate R . (1997): Comparison of efficacy of social skills training for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry 154: 424–425
Kraepelin E . (1971): Dementia Praecox and Paraphrenia [original work published in 1919]. New York, NY, Krieger
Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O . (1997): Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170: 18–22
Meltzer HY, Sommers AA, Luchins DJ . (1986): The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol 6: 329–338
Moller JH, Muller H, Borison RL, Schooler NR, Chouinard G . (1996): A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 245: 45–49
Nibuya M, Kanba S, Sekiya U, Suzuki E, Matsuo Y, Kinoshita N, Shintani F, Yagi G, Asai M . (1995): Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement. Biol Psychiatry 38: 50–56
Opler LA, Albert D, Ramirez PM . (1994): Psychopharmacologic treatment of negative schizophrenic symptoms. Comprehen Psychiatry 35: 16–28
Paillere-Martinot ML, Lecrubier Y, Martinot JL, Aubin F . (1995): Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 152: 130–134
Ribeyre JM, Lesieur P, Varoquaux O, Dollfus S, Pays M, Petit M . (1994): A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia. Biol Psychiatry 36: 230–236
Rosenheck R, Dunn L, Peszke M, Cramer J, Xu W, Thomas J, Charney D . (1999): Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Am J Psychiatry 156: 88–93
Ross DE, Thaker GK, Buchanan RW, Lahti AC, Medoff D, Bartko JJ, Moran M, Hartley J . (1996): Association of abnormal smooth pursuit eye movements with the deficit syndrome in schizophrenic patients. Am J Psychiatry 153: 1158–1165
Strauss JS, Carpenter WT Jr, Bartko JJ . (1974): The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull 11: 61–69
Tamminga CA, Thaker GK, Buchanan RW, Kirkpatrick B, Alphs LD, Carpenter WT, Chase TN . (1992): Limbic system abnormalities identified in schizophrenia using PET/FDG and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 49: 522–530
Thibaut F, Ribeyre JM, Dourmap N, Menard JF, Dollfus S, Petit M . (1998): Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia. Biol Psychiatry 43: 24–30
Tollefson GD, Sanger TM . (1997): Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154: 466–474
Waltrip RW II, Buchanan RW, Carpenter WT Jr, Kirkpatrick B, Summerfelt A, Breier A, Rubin SA, Carbone KM . (1997): Borna disease virus antibodies and the deficit syndrome of schizophrenia. Schizophr Res 23: 253–258
Acknowledgements
Supported in part by PHS grants MH45074, MH40279, MH35996, MH48225, and MH56026, and grants from the National Alliance for Research on Schizophrenia and Depression.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kirkpatrick, B., Kopelowicz, A., Buchanan, R. et al. Assessing the Efficacy of Treatments for the Deficit Syndrome of Schizophrenia. Neuropsychopharmacol 22, 303–310 (2000). https://doi.org/10.1016/S0893-133X(99)00122-0
Received:
Revised:
Accepted:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(99)00122-0
Keywords
This article is cited by
-
Transcranial Magnetic Stimulation in the Treatment of Positive, Negative, and Cognitive Symptoms of Psychosis
Current Behavioral Neuroscience Reports (2023)
-
The efficacy of transcranial magnetic stimulation (TMS) for negative symptoms in schizophrenia: a systematic review and meta-analysis
Schizophrenia (2022)
-
5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice
Neuropsychopharmacology (2017)
-
The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities
Neuropsychopharmacology (2008)
